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The era of open heart surgery began with a variety of ingenioustechniques directed at closure of the secundum atrial septal defect(ASD).1-4 Indeed, the first successful application of cardiopulmonarybypass was for this purpose.5 Direct vision intracardiac surgery owesits origins to the ASD. Over the past half century surgical closure ofa secundum ASD has become a low-risk and highly successful
procedure.6,7 In addition to being bread and butter for the heart surgeon, ASD
closure has become a valuable procedure for introducing the cardiothoracic resident
to true “open” heart surgery. Until recently, cardiovascular surgeons have felt
privileged and (maybe, self-importantly) exclusively qualified to close these defects.
Now our turf is being challenged once again by some bright and innovative
nonsurgeons, the interventional cardiologists. Our cardiology colleagues, demon-
strating ingenuity not unlike that of our predecessors in cardiac surgery, have
developed techniques to close interatrial communications with a catheter! Is trans-
catheter ASD closure a safe and reasonable approach? Is it a threat to our livelihood
or our ability to train residents? What role should we play in its introduction?
The first successful transcatheter closure of an ASD occurred a quarter of a
century ago. Thus, it is somewhat surprising that the technique is only now
becoming an alternative to surgery. The initial report in 1976 by King and Mills8
demonstrated the feasibility of the approach, but the requirement for a very large
(23F) delivery catheter precluded its application to the pediatric population. In the
mid-1980s, based on a device initially designed by William Rashkind,9 James Lock
and C.R. Bard, Inc (Murray Hill, NJ) applied the double-umbrella concept to
develop the clamshell ASD occlusion device,10 which could be introduced through
an 11F femoral sheath. The Bard clamshell was introduced into a prospective
nonrandomized multicenter Food and Drug Administration (FDA) Investigational
Device Exemption (IDE) clinical trial in 1989.11 More than 500 patients received the
device. ASD closure was successful in the majority of patients with some procedure-
related morbidity, no midterm morbidity, and no mortality. Success was most likely
for central secundum defects less than 20 mm in diameter. As enthusiasm was
building for the device, incidental breaks in the metal arms were noted. Although
few, if any, serious sequelae developed from these breaks, it was clear that a
material and design change was necessary and the device was withdrawn. Despite
this design failure, this initial clinical experience indicated that many ASDs could
be safely and effectively closed in the catheterization laboratory. Another ASD
closure device, the Sideris buttoned occluder (Custom Medical Devices, Amarillo,
Tex), has been implanted in more than 400 patients with similar results.12 At least
three other ASD occluder devices (Das AngelWings device13 [Microventa Corp,
White-Bear Lake, Minn], ASDOS device14 [Osypka Corporation, Rheinfelden,
Germany], and Amplatzer device15 [AGA Medical Corp, Golden Valley, Minn])
have been introduced and are being evaluated in clinical trials. Because of FDA
restrictions, most of the experience with these newer devices has been obtained
outside of the United States. In September of 1999, however, the FDA granted
approval for the selective use of the latest generation of the clamshell device, the
CardioSEAL Septal Occluder (Nitinol Medical Technology, Inc, Boston, Mass).
Application of the device was limited to the closure of Fontan fenestrations and
apical ventricular septal defects. In January of 2000 the closure of a patent foramen
ovale for paradoxic embolization was added to the acceptable indications. It may not
be long before the FDA adds small centrally located secundum ASDs to this list.
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Thus, the writing is on the wall! Transcatheter closure is
becoming an accepted technique for closure of patent fora-
men ovales and some ASDs. Because it can be performed
without general anesthesia, without cardiopulmonary by-
pass, and without an incision, the technique must be con-
sidered an attractive alternative to conventional surgical
closure. Although the cost of the device and the implanta-
tion facilities may be similar to those of surgical closure,
hospitalization is shortened or eliminated and time off from
work is greatly reduced. Let’s admit it. Transcatheter ASD
closure will be the best approach for some patients.
Acceptance of the value of this technique, however, does
not relieve the surgeon of an important role in its introduc-
tion into our local or regional cardiovascular programs. A
close working relationship between the surgeon and the
interventionalist will permit successful and safe application
of this technique. The surgeon’s role continues to be that of
patient advocate, recognizing favorable and unfavorable
anatomy, and participating in the selection of patients for
the transcatheter approach. Ostium primum and sinus veno-
sus ASDs, as well as large secundum defects with limited
septal margins, are more suitable for closure under direct
vision with cardiopulmonary bypass. Therefore, patients
will continue to be available for the training of our residents.
The other role the surgeon must play is that of backup in case
of failure or device embolization. As always, the surgeon
remains uniquely qualified for dealing with failures in the
catheterization laboratory. The accompanying article by Berdat
and associates16 describes the experience of a surgical team
dealing with complications of transcatheter closure techniques.
The fact that complications have occurred with these
techniques has not and should not dissuade its proponents
from continuing to apply the devices. With any new tech-
nique a certain experiential learning curve is expected. In
the present article 8% of patients required surgical interven-
tion, an incidence that is likely to decrease with time. The
average ASD diameter of 25 mm for patients coming to
surgical intervention supports the concept that defect size is
an important factor in selecting patients for device closure.
Lessons learned from their experience are well described by
the authors. The most common failure in their experience
was malposition of the device resulting in a residual ASD,
further evidence suggesting a problem with patient selec-
tion. The make of septal occluder may also be a factor, but
comparative data in this regard are not yet available. More
important, when surgery is required for a complication,
conventional surgical techniques are successful with low
morbidity. On the basis of the experience from Bern, it
could be cogently argued that although surgery became
necessary in some cases, transcatheter procedures saved
more than 90% of patients from an open heart operation.
The one death in the series, resulting from perforation of the
left ventricle during percutaneous attempts to recover a
dislocated device, should serve as an important warning that
this new technique does have potential for mortality and
must not be taken lightly. As transcatheter ASD closure is
introduced into our medical communities, let us continue to
foster a careful and deliberate collaboration between sur-
geon and interventionalist.
Finally, let us not forget that the ultimate success of any
technique must be evaluated over the long term. A promis-
ing early result does not guarantee a favorable late outcome.
Our own experience with the Ionescu-Shiley and convexo-
concave Bjo¨rk-Shiley valve prostheses attests to the impor-
tance of continued follow-up and critical evaluation for
years to come. Surgical closure of an ASD has stood the test
of time. Will the same be true for transcatheter closure?
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